Improving Assay Sensitivity in Analgesic Proof-of-Concept Studies: Osteoarthritis

Similar documents
PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

A Phase 2 Study of HTX-011 in the Management of Post-Operative Pain Positive Top-Line Results

NIMULID MD. 1. Introduction. 2. Nimulid MD Drug delivery system

Medical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo

Study Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch

Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)

Understanding When to Employ IVR and IWR independently or in Combination

Managing canine osteoarthritis: What has proven benefits?

2.0 Synopsis. Vicodin CR (ABT-712) M Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:

4/18/14. Background. Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients. Background. Signs and Symptoms of Withdrawal

TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Tension Type Headaches

Comparison/Control Groups. Mary Foulkes, PhD Johns Hopkins University

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Proposal for deletion Codeine phosphate tablets for pain in children

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C

Treatment for Adolescent Substance Use Disorders: What Works?

The Chemical Coper Steven D. Passik, PhD

BEST in MH clinical question-answering service

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

Frequent headache is defined as headaches 15 days/month and daily. Course of Frequent/Daily Headache in the General Population and in Medical Practice

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author

ISCTM ADAPTIVE DESIGN WORKING GROUP

1. Which of the following would NOT be an appropriate choice for postoperative pain. C. Oral oxycodone 5 mg po every 4 to 6 hours as needed for pain

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

Robot-Assisted Stroke Rehabilitation

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

Guideline on the clinical development of medicinal products intended for the treatment of pain

What alternatives are there to the use of opioid analgesics in the treatment of chronic pain in light of existing evidence and its limitations?

A HISTORICAL PERSPECTIVE ON HUMAN ABUSE LIABILITY STUDIES. Donald R Jasinski, MD

A. Approval for the indications of osteoarthritis and rheumatoid arthritis at a dose of 10mg/day and dysmenorrhea at a dose of 20-mg bid as needed.

Conners' Continuous Performance Test II (CPT II V.5)

Guidance for Industry Migraine: Developing Drugs for Acute Treatment

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

Double-Blind Trial of Fluoxetine: Chronic Daily Headache and Migraine

Tension-type headache Non-pharmacological and pharmacological treatment

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

Robert Okwemba, BSPHS, Pharm.D Philadelphia College of Pharmacy

Comparative Effectiveness Research

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Drug Class Review Neuropathic Pain

CLINICAL TRIALS: Part 2 of 2

Alison White Devang Rai Richard Chye

A. Ketorolac*** B. Naproxen C. Ibuprofen D. Celecoxib

Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac

Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Tension-type headache Non-pharmacological and pharmacological treatment

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL MEDICINAL PRODUCTS INTENDED FOR THE TREATMENT OF NEUROPATHIC PAIN

Immunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Study Design and Statistical Analysis

Knee Pain/Osteoarthritis: Occupational Therapy Approaches

10. Analysis of Longitudinal Studies Repeat-measures analysis

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients

Continuous Performance Test 3 rd Edition. C. Keith Conners, Ph.D.

Acute Pain Management in the Opioid Dependent Patient. Maripat Welz-Bosna MSN, CRNP-BC

Bupivacaine liposomal injection was recently

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Bioavailability / Bioequivalence

Background & Significance

Guideline on the clinical development of medicinal products intended for the treatment of pain

Treatment of Prescription Opioid Dependence

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.

Consider the following from a recent study published in the British Journal of Medicine(3):

Jennifer Sharpe Potter, PhD, MPH Associate Professor Division of Alcohol and Drug Addiction Department of Psychiatry

REPORTING ON PARTICIPANT DISPOSITION IN CLINICAL TRIALS. Dennis C. Turk, Ph.D. 1 University of Washington School of Medicine

Focus on Assessment. Teaching Pain Assessment and Management: Pearls for Caring for Patients with Pain. #1. Pain is a Universal Experience.

CHOICE OF CONTROL GROUP AND RELATED ISSUES IN CLINICAL TRIALS E10

Guidance for Industry

Article details. Abstract. Version 1

Headaches in Children How to Manage Difficult Headaches

Stat 20: Intro to Probability and Statistics

October We hope that our tool will be a useful aid in your efforts to improve pain management in your setting. Sincerely,

THE COMMONWEALTH OF MASSACHUSETTS Department of Industrial Accidents

[Informed Consent Form for ] Name the group of individuals for whom this consent is written. Explanation Example

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Guidance for Industry

ADHD PRACTISE PARAMETER. IRSHAAD SHAFFEEULLAH, M.D. A diplomate American Board of CHILD AND ADOLESCENT PSYCHIATRY

Pain Management in the Critically ill Patient

33 % of whiplash patients develop. headaches originating from the upper. cervical spine

TREATMENT-RESISTANT DEPRESSION AND ANXIETY

Cytori Therapeutics NASDAQ: CYTX

Pain Medication Taper Regimen Time frame to taper off days

The Product Review Life Cycle A Brief Overview

Treatment of Anxiety in the Methadone Maintained Patient

QT analysis: A guide for statistical programmers. Prabhakar Munkampalli Statistical Analyst II Hyderabad, 7 th September 2012

8 General discussion. Chapter 8: general discussion 95

Transcription:

Improving Assay Sensitivity in Analgesic Proof-of-Concept Studies: Osteoarthritis Nathaniel Katz, MD, MS Analgesic Solutions, Inc. Tufts University School of Medicine ADEPT, Bermuda, March 25, 2011

Objectives To present a conceptual framework for approaching the problem of assay sensitivity To provide examples of efforts to improve assay sensitivity, focusing on osteoarthritis

Why do effect sizes of identical treatments differ across studies? Actual biological effect of drug differs when studied by different authors Random chance: God rolls dice in our studies Aspects of study design or conduct influence observed effect size Zhang et al, Osteoarthritis & Cartilage, 2010

International Conference on Harmonization. E10: Choice of control groups and related issues in clinical trials. Assay Sensitivity a property of a clinical trial defined as the ability to distinguish an effective treatment from a less effective or ineffective treatment Pain ACTIVE - Std Dev P Pain PBO

Ray Houde (1916-2006) Louis Lasagna (1923-2003) Mitchell B. Max (1949-2008)

Ibuprofen Liquigel 400 mg for Dental Pain Hersh E, et al, Clin Ther, 2000; Olson N, et al, J Clin Pharm, 2001

Relative Standard Effect Size SPID6 Ibuprofen liquigel 400mg vs. placebo: Hersh Delta 7.61 SD 4.85 SES 1.57 Sunshine 9.17 4.5 2.04 Sunshine has 30% higher SES (Equivalent to reducing sample size from 100/arm to 60/arm)

Pregabalin vs. Placebo in Inguinal Herniorrhaphy Lotus Research (n = 126) All 24 Other Sites (n = 274) Primary endpoint: 0.81 0.56 SD 2.25 2.56 SES ( /SD) 0.360 0.219 N for 80% power, alpha = 0.05 Subjects enrolled per per month Overall Performance (time to 80% power) *utilizing one site at Lotus 244 658 23.2 0.75 10.5 months* 36.6 months ** **utilizing 24 non-lotus sites in concert Singla N, American Pain Society, 2010

Implications The standardized effect size of a treatment is not fixed, but elastic depending on methodologic factors that determine assay sensitivity We can figure out what those methodologic factors are We can intentionally implement them in clinical trials to increase assay sensitivity

Approaches Meta-analysis By study Within-patient Experimental

Reasons for Failure: Opioid Trials Trial structure Crossover and withdrawal better than parallel treatment Dosing Titration better than non-titration Flexible better than fixed Concomitant analgesics Prohibited better than allowed Rescue Prohibited better than allowed Primary endpoint AUC better than landmark Number of sites The fewer the better Katz N, et al, Neurology, 2005

Standardized effect size vs. number of sites, opioid trials Decreasing SES from 1 to 0.25 can increase sample size requirements from 20 to 250 patients/arm Adapted from Katz N, et al, Neurology, 2005

Methodologic Factors Study Level Study structure Number of arms Duration Number of visits Baseline duration Dose, administration Rescue meds Concomitant analgesics Protocol concealment Site training Investigator experience Patient Level Diagnosis Pain duration Co-morbidities Psychiatric status Concomitant analgesics Demographics Baseline pain intensity Baseline pain variability Diary compliance Expectation of pain relief Previous experience

Predictors of positive studies: neuropathic pain, n=90 studies Katz J, et al, Neurology, 2008

Sample size requirements to detect differences in SES by methodologic feature Difference in SES Total N of studies Total N of Patients 0.1 74 12561 0.2 20 3142 0.3 12 1398 0.4 8 787 0.5 6 505 Increasing SES from 0.3 to 0.4 can decrease sample size requirements per arm from 175 to 100

Meta-analytic methods Meta-analysis can shed light on the relationship between methodologic features and study outcome Databases will need to be large, and include within-patient data We should be looking for trends and testing candidate approaches experimentally

Experimental Approaches Single Site Studies What generates a pain score? Experimental Noise FAST Pain Matcher Random Error True + Pain Score Patient Innate Reporting Capability + Measure Error = Reported Pain Score Validity Reliability Responsiveness

Psychophysical Assessment(Ф) Experimental Pain Rating Subjects rate 7 heat stimuli for pain level 7 times using VAS

VAS Rating VAS Rating Psychophysical Profile Samples Ф Evoked Thermal Pain Ratings 100 Low variation reporter (CoV=.42, ICC=.91, R 2 =.72). 80 60 40 20 0 42 43 44 45 46 47 48 49 50 51 52 Temperature ( o C) 100 Evoked Thermal Pain Ratings High variation reporter (CoV=.76, ICC=.58, R 2 =.47). 80 60 40 20 0 42 43 44 45 46 47 48 49 50 51 52 Temperature ( o C)

Frequency Plots for Pain Reporting Skill N= 79 Mean =.74 SD=.31 CoV Subjects demonstrated a large range of performance in pain reporting skill as indexed by CoV, ICC, and R 2.

Pre- vs. post-exercise VAS scores in good vs. bad pain reporters

Stay Tuned Single-site POC study in knee OA recently completed FAST assessment demonstrated to be reliable After excluding high variability pain reporters, NSAID separated from placebo in 31 subjects on primary endpoint of staircase-evoked pain

Pain Matching Subjects adjust thermode temp until pain heat = pain OA (forced choice staircase procedure)

PM Score ( o C) VAS Score 6 5 4 Delta Exercise Pain Results: Change in pain significantly different for PM not VAS SES 3 2 1 0 Pre-exercise PM C p<.05 Post-exercise 45 44 43 42 41 40 39 38 Pre-exercise Post-exercise VAS PM

Other explorations of alternative pain measures P<.05 Eisenach J, et al, Pain, 2003

Pain-Activity Composites Actiwatch -Score Phillips-Respironics, Inc.

P=.115 Pain-Activity Composites in an OA RCT, Celecoxib vs. Placebo, n=43 Pain alone: >20% improved from baseline; liberal: pain improved >20% OR activity improved >10%; conservative: pain pain improved >20% OR activity improved >10% WITHOUT deterioration in the other measure.

Bedside Sensory Testing Kit - OA

Sensory Categories in OA: Pilot Study Αlpha =.59 -.72

Conclusions Meta-analytic methods can be used to shed light on the impact of methodologic factors on study outcome Experimental methods can be used to develop and test study design methods to increase assay sensitivity Success will require resources, perseverance, and patience: hitting home runs on the first swing is unlikely